BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 8646674)

  • 21. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
    Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
    Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
    Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
    Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
    Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma.
    Iwadou S; Nouso K; Kuwaki K; Kobayashi Y; Nakamura S; Tanaka H; Miyoshi K; Ohnishi H; Miyake Y; Shiraha H; Iwasaki Y; Shiratori Y; Yamamoto K
    Liver Int; 2010 Aug; 30(7):1027-32. PubMed ID: 20492506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
    Ishida H; Matsuo S; Inoue Y
    Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
    Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
    Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
    Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
    Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Kuzuya T; Asahina Y; Tsuchiya K; Tanaka K; Suzuki Y; Hoshioka T; Tamaki S; Kato T; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Izumi N
    Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
    Miura N; Maruyama S; Oyama K; Horie Y; Kohno M; Noma E; Sakaguchi S; Nagashima M; Kudo M; Kishimoto Y; Kawasaki H; Hasegawa J; Shiota G
    Oncology; 2007; 72 Suppl 1():45-51. PubMed ID: 18087181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
    Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
    Tanabe Y; Ohnishi K; Nomura F; Iida S
    Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.